Rock-Solid Triferic Heads Toward ODAC Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Rockwell Medical Inc.’s ferric pyrophosphate seems poised to help firm’s emerging dialysis franchise if FDA is comfortable with an imbalance of deaths deemed not related to the drug seen in pivotal trials.